REG - Oxford Biomedica PLC - Subscription of shares by Institut Mérieux

Oxford BioMedicaAnnouncement

18/06/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240618:nRSR7819Sa&default-theme=true

RNS Number : 7819S  Oxford Biomedica PLC  18 June 2024

 

 

 

Subscription of shares by Institut Mérieux

Oxford, UK - 18 June 2024: Oxford Biomedica plc (LSE:OXB) ("Oxford
Biomedica", "OXB" or "the Company"), a quality and innovation-led cell and
gene therapy CDMO, today announces that an application has been made to the
Financial Conduct Authority and the London Stock Exchange for the admission to
(i) the Premium segment of the Official List and (ii) to trading on the London
Stock Exchange for the listing of 5,201,107 new ordinary shares of 50 pence
each ("Admission"), representing 4.9% of the Company's enlarged issued share
capital following the issue of such new ordinary shares. The new ordinary
shares will be issued on a non pre-emptive basis utilising the authority
granted at the Group's 2023 AGM.

The Admission is in respect of a EUR 20 million investment (£16.9 million) by
TSGH SAS, a subsidiary of Institut Mérieux SA ("Institut Mérieux") which has
been made at a share price of 325p per ordinary share, being the 30-day VWAP
to closing on 17 June 2024. As previously communicated, this investment
follows Oxford Biomedica's acquisition of ABL Europe SAS, (since renamed
Oxford Biomedica (France) SAS ("OXB France")) from Institut Mérieux, which
was completed on 29 January 2024. The announcement can be found here
(https://oxb.com/oxford-biomedica-completes-acquisition-of-abl-europe/) . The
acquisition of OXB France has enhanced OXB's bioprocessing and manufacturing
footprint in the EU, strengthening the Group's multi-vector, multi-site model
and adding specialised expertise in the development and manufacturing of
solutions for biotech and biopharma companies.

 

The Admission is expected to occur on 19 June 2024. Following Admission and
following the previously announced transaction and purchases in the open
market, Institut Mérieux will hold a 10.9% stake in Oxford Biomedica, making
it a major, long-term shareholder and further underpinning conviction in OXB's
strategy.

 

-Ends-

 

 For further information, please contact:

 Oxford Biomedica plc:                     Tel: +44 (0)1865 783 000

 Natalie Walter, Company Secretary

 

 

ABOUT OXFORD BIOMEDICA

 

Oxford Biomedica (LSE: OXB) is a quality and innovation-led contract
development and manufacturing organisation (CDMO) in cell and gene therapy
with a mission to enable its clients to deliver life changing therapies to
patients around the world.

 

One of the original pioneers in cell and gene therapy, OXB has more than 25
years of experience in viral vectors; the driving force behind the majority of
cell and gene therapies. OXB collaborates with some of the world's most
innovative pharmaceutical and biotechnology companies, providing viral vector
development and manufacturing expertise in lentivirus, adeno-associated virus
(AAV), adenovirus, and other viral vector types. Oxford Biomedica's
world-class capabilities span from early-stage development to
commercialisation. These capabilities are supported by robust
quality-assurance systems, analytical methods and depth of regulatory
expertise.

 

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford,
UK. It has bioprocessing and manufacturing facilities across Oxfordshire,
UK, Lyon and Strasbourg, France, and near Boston, MA, US. Learn more
at www.oxb.com (https://www.oxb.com/) , and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica/)  and YouTube
(https://www.youtube.com/user/OxfordBioMedica) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEQKOBBKBKBDAD